StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL – Free Report) in a report released on Friday. The firm issued a sell rating on the medical technology company’s stock.
BIOLASE Price Performance
NASDAQ BIOL opened at $0.15 on Friday. BIOLASE has a 12 month low of $0.13 and a 12 month high of $32.09. The company has a debt-to-equity ratio of 34.06, a current ratio of 1.26 and a quick ratio of 0.68. The stock’s fifty day moving average price is $0.15 and its 200-day moving average price is $0.82.
BIOLASE (NASDAQ:BIOL – Get Free Report) last announced its quarterly earnings data on Thursday, March 21st. The medical technology company reported ($1.76) EPS for the quarter. The firm had revenue of $13.49 million for the quarter. BIOLASE had a negative net margin of 41.97% and a negative return on equity of 555.22%.
About BIOLASE
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.
Featured Stories
- Five stocks we like better than BIOLASE
- How Investors Can Find the Best Cheap Dividend Stocks
- MarketBeat Week in Review – 4/22 – 4/26
- Why is the Ex-Dividend Date Significant to Investors?
- 3 Stocks Leading the U.S. Agriculture Comeback
- What is a Bond Market Holiday? How to Invest and Trade
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.
